Seijas-Jerónimo R, Guzmán-Hidalgo M, Guerra-GonzálezGail L, Fuentes-Seijas M, Díaz-Izarra AJ

Language: Spanish
References: 21
Page: 38-42
PDF size: 534.62 Kb.

ABSTRACT

The desmoid tumor also known as muscle-aponeurotic fibromatosis, aggressive fibromatosis, deep fibromatosis, no metastatic fibrosarcoma and fibrosarcoma grade I, is an aggressive fibromatosis of slow and gradual installation .There are discrepancies regarding optimal treatment; because of its benign nature surgery is justified, but in some cases, chemotherapy has been administered, when evolution is not the usual and has existed response to this medication. Desmoid tumors can be considered as sarcomas with very low virulence. Conventional wisdom would indicate that such tumors would not have any response to chemotherapy, but the opposite happens. It has an incidence of 3-4 cases per million, with a peak between 25 and 35 years of age, affecting mainly females. Presents high probability of recurrence. It usually occurs in women in the postpartum period, the rectus abdominis and the scars of abdominal surgery. But can appear in any muscle. We present the case of a female aged 27 with APP health until November 2010 when she was diagnosed with left renal calculi and subjected to partial nephrectomy lumbotomy. One year and nine months after, having eight weeks of pregnancy, in the area of the scar a tumor appears. The tumor had rapid growth hard consistency without being painful, after diagnostic procedures, it was concluded as a desmoid tumor, expressing their diagnosis and treatment, the case was diagnosed in the Camilo Cienfuegos Hospital of Sancti Spiritus Cuba.

REFERENCES

1. Hosalkar HS, Torbert JT, Fox EJ, Delaney TF, Aboulafia AJ, Lackman RD. Musculoskeletal desmoid tumors. Journal of the American Academy of Orthopaedic Surgery, 2008.

2. Pakos EE, Tsekeris PG, Goussia AC. Desmoidtumours of the extremities and trunk: a review of the literature. International Orthopaedics. 2005;29(4):210–213.

3. Meazza C, Bisogno G, Gronchi A, et al. Aggressive fibromatosis in children and adolescents: the italian experience. Cancer. 2010;116(1):233–240.

4. García EBG, Knoers NV. Gardner's syndrome (familial adenomatous polyposis): a cilia-related disorder. The Lancet Oncology. 2009;10(7):727–735.

5. Arturo Mahiquez. Tumores y lesiones tumor like del tejido fibroso. American Academy of Orthopaedic Surgeons: Actualizaciones en Cirugia Ortopédica y Traumatología. Volumen 4. Garsi. Madrid 1993.

6. Maria Elena Hijós Bitrician. Tumor de smoide extraabdominal. Gestio de Serveis Sanitaris Hospital Santa Maria. Barcelona 2011.

7. Giarola M, Wells D, Mondini P, et al. Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoidtumours. British Journal of Cancer. 1998;78(5):582–587.

8. Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors—a characterization of patients seen at Mayo Clinic 1976–1999. Familial Cancer. 2006;5(2):191–194.

9. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LMH, Dekkers OM, Hogendoorn PCW, Vasen HFA. A nationwide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. International Journal of Cancer. 2011;129(1):256–261.

10. H. Nieuwenhuis, M. Casparie, L. M. H. Mathus-Vliegen, O. M. Dekkers.Extrabdominal desmoid tumores associated with familia ladenomatores polyposis. www.hindawi.com/journals/sarcoma/2012/726537/

11. Dalén BPM, Bergh PM, Gunterberg BUP. Desmoid tumors: a clinical review of 30 patients with more than 20 years' follow-up. Acta Orthopa edica Scandinavica. 2003;74(4):455–459.

12. Ozger H, Eralp L, Toker B, Ağaoğlu F, Dizdar Y. Evaluation of prognostic factors affecting recurrences and disease-free survival in extra-abdominal desmoid tumors. Acta Orthopaedica et TraumatologicaTurcica. 2007;41(4):291–294.

13. Jenkins NH, Freedman LS, McKibbin B. Spontaneous regression of a desmoidtumour. Journal of Bone and Joint Surgery. 1986;68(5):780–781.

14. Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors) European Journal of Surgical Oncology. 2009;35(1):3–10.

15. Ishitani T, Ninomiya-Tsuji J, Matsumoto K. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogenactivated protein kinase-related Nemo-like kinasedependent phosphorylation in Wnt/β-catenin signaling. Molecular and Cellular Biology. 2003;23(4):1379–1389.

16. Kong Y, Poon R, Nadesan P, et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Research. 2004;64(16):5795–5803.

17. Matono H, Tamiya S, Yokoyama R, et al. Abnormalities of the Wnt/β-catenin signalling pathway induce tumour progression in sporadic desmoidtumours: correlation between β-catenin widespread nuclear expression and VEGF overexpression. Histopathology. 2011;59(3):368–367.

18. Picariello L, Tonelli F, Brandi ML. Selective oestrogen receptor modulators in desmoidtumours. Expert Opinion on Investigational Drugs. 2004;13(11):1457–1468.

19. O'Keefe F, Kim EE, Wallace S. Magnetic resonance imaging inaggressive fibromatosis. Clinical Radiology. 1990;42(3):170–173.

20. Owens CL, Sharma R, Ali SZ. Deep fibromatosis (desmoid tumor): cytopathologic characteristics, clinicoradiologic features, and immunohistochemical findings on fine-needle aspiration. Cancer. 2007;111(3):166–172.

21. Nuyttens JJ, Rust PF, Thomas CR, Jr., Turrisi AT., III Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer. 2000;88(7):1517–1.